Wojciech Jerzy Piotrowski1, Iwona Bestry2, Adam J Białas3, Piotr W Boros4, Piotr Grzanka5, Ewa Jassem6, Dariusz Jastrzębski7, Dariusz Klimczak8, Renata Langfort9, Katarzyna Lewandowska10, Sebastian Majewski11, Magdalena M Martusewicz-Boros12, Karina Onisch2, Elżbieta Puścińska13, Alicja Siemińska14, Małgorzata Sobiecka10, Małgorzata Szołkowska9, Elżbieta Wiatr12, Gracjan Wilczyński15, Dariusz Ziora6, Jan Kuś10. 1. Department of Pneumology and Allergy, Medical University of Lodz, Lodz, Poland. wojciech.piotrowski@umed.lodz.pl. 2. Department of Radiology, National Tuberculosis and Lung Diseases Research Institute in Warsaw, Poland. 3. Department of Pathobiology of Respiratory Diseases, Medical University of Lodz, Poland. 4. Lung Pathophysiology Department, National Tuberculosis and Lung Diseases Research Institute in Warsaw, Poland. 5. Department of Radiology, Voivodeship Hospital in Opole, Poland. 6. Department of Allergology and Pneumonology, Medical University of Gdansk, Poland. 7. Department of Lung Diseases and Tuberculosis, Medical University of Silesia, Zabrze, Poland. 8. Patient, Polish Society for IPF Patients' Support, Poland. 9. Department of Pathology, National Tuberculosis and Lung Diseases Research Institute in Warsaw. 10. First Lung Diseases Department, National Tuberculosis and Lung Diseases Research Institute in Warsaw, Poland. 11. Department of Pneumology and Allergy, Medical University of Lodz, Poland. 12. Third Lung Diseases and Oncology Department, National Tuberculosis and Lung Diseases Research Institute in Warsaw. 13. Second Department of Respiratory Medicine, National Tuberculosis and Lung Diseases Research Institute in Warsaw, Poland. 14. Allergology Department, Medical University of Gdansk, Poland. 15. Patient, not affiliated.
Abstract
INTRODUCTION: This document presents the guidelines of the Polish Respiratory Society (PTChP, Polskie Towarzystwo Chorób Płuc) for diagnosis and treatment of idiopathic pulmonary fibrosis (IPF), developed by agroup of Polish experts. MATERIAL AND METHODS: The recommendations were developed in the form of answers to previously formulated questions concer-ning everyday diagnostic and therapeutic challenges. They were developed based on acurrent literature review using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. RESULTS: We formulated 28 recommendations for diagnosis (8), pharmacological treatment (12) as well as non-pharma-cological and palliative therapy (8). The experts suggest that surgical lung biopsy (SLB) not be performed in patients with the probable usual interstitial pneumonia (UIP) pattern, with an appropriate clinical context and unanimous opinion of a multidisciplinary team. The experts recommend using antifibrotic agents in IPF patients and suggest their use irrespective of the degree of functional impairment. As regards non-pharmacological and palliative treatment, strong re-commendations were formulated regarding pulmonary rehabilitation, oxygen therapy (in patients with chronic respiratory failure), preventive vaccinations as well as referring IPF patients to transplant centres. Table 1 presents an aggregate list of recommendations. CONCLUSIONS: The Polish Respiratory Society Working Group developed guidelines for IPF diagnosis and treatment.
INTRODUCTION: This document presents the guidelines of the Polish Respiratory Society (PTChP, Polskie Towarzystwo Chorób Płuc) for diagnosis and treatment of idiopathic pulmonary fibrosis (IPF), developed by agroup of Polish experts. MATERIAL AND METHODS: The recommendations were developed in the form of answers to previously formulated questions concer-ning everyday diagnostic and therapeutic challenges. They were developed based on acurrent literature review using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. RESULTS: We formulated 28 recommendations for diagnosis (8), pharmacological treatment (12) as well as non-pharma-cological and palliative therapy (8). The experts suggest that surgical lung biopsy (SLB) not be performed in patients with the probable usual interstitial pneumonia (UIP) pattern, with an appropriate clinical context and unanimous opinion of a multidisciplinary team. The experts recommend using antifibrotic agents in IPFpatients and suggest their use irrespective of the degree of functional impairment. As regards non-pharmacological and palliative treatment, strong re-commendations were formulated regarding pulmonary rehabilitation, oxygen therapy (in patients with chronic respiratory failure), preventive vaccinations as well as referring IPFpatients to transplant centres. Table 1 presents an aggregate list of recommendations. CONCLUSIONS: The Polish Respiratory Society Working Group developed guidelines for IPF diagnosis and treatment.
Authors: Katarzyna Górska; Marta Maskey-Warzęchowska; Małgorzata Barnaś; Adam Białas; Adam Barczyk; Hanna Jagielska-Len; Ewa Jassem; Aleksander Kania; Katarzyna Lewandowska; Sebastian Majewski; Magdalena M Martusewicz-Boros; Wojciech J Piotrowski; Alicja Siemińska; Krzysztof Sładek; Małgorzata Sobiecka; Marzena Trzaska-Sobczak; Witold Tomkowski; Beata Żołnowska; Rafał Krenke Journal: Ther Adv Chronic Dis Date: 2022-08-22 Impact factor: 4.970